Medical/Pharmaceuticals
MediThinQ and Synovis Micro Companies Alliance, Inc. Announce Strategic Global Distribution Agreement to Redefine Microsurgery with the SHIYA 3D Visualization Platform
Multi-year exclusive agreement to expand access to next-generation 3D surgical visualization worldwide SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- MediThinQ, a South Korea-based innovator in surgical visualization technologies, has entered into an exclusive multi-year distribution agreemen...
2026-06-18 22:01
1717
Frost & Sullivan Identifies Virtual Healthcare Assistants as a Transformational Force in Healthcare Delivery
New analysis highlights significant growth opportunities in patient- and clinician-facing AI assistants as healthcare organizations seek to improve efficiency, patient engagement, and care outcomes LONDON, June 18, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis, Innovations and Growth O...
2026-06-18 21:07
1146
ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing
ZEISS Medical Technology and Envision Health Technologies will collaborate to advance the next generation of patient-accessible, software-driven visual function testing while maintaining a science-first approach to glaucoma care. JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technolo...
2026-06-18 21:00
1006
Navigating Primary Biliary Cholangitis in Singapore: Addressing the Diagnostic Gap and the Next-Generation Therapies
* 90% Female Prevalence: PBC is a critical women's health issue, yet symptoms like crushing fatigue and relentless itching are frequently misdiagnosed as menopause or stress. * 30-Year Innovation Gap: This new class of therapy is the first major breakthrough in three decades for the 40% of pa...
2026-06-18 17:03
1884
AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech's Zabopegdutide in Phase 2 MASH Trial
SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech, today announced positive results from HistoIndex's AI-based quantitative analysis of liver biopsy samples from the Phase 2 cl...
2026-06-18 10:00
3012
ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units
JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today that the company held a signing ceremony with the Aier Eye Hospital Group, entering into a strategic agreement for the purchase and installation of 25 ZEISS VISUMAX 800 femtosecond lasers across multiple Aier Ey...
2026-06-18 08:49
2177
Tinnitus Quest Builds Momentum with Oxford Research Study, New Funding Call, and Second Tinnitus Hackathon
OXFORD, England, June 18, 2026 /PRNewswire/ -- Tinnitus Quest
2026-06-18 03:55
2892
FiberSense Continuous Glucose Monitoring (CGM) System obtains CE mark as commercial launch preparations begin
Major regulatory milestone paves the way for commercialization and marks first step toward broader CxM biomarker sensing strategy BASEL, Switzerland, June 17, 2026 /PRNewswire/ -- FiberSense AG ("FiberSense") today announced that the FiberSense Continuous Glucose Monitoring (CGM) System has obta...
2026-06-17 17:06
2578
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase 2 clinical proof-of-concept trial (NOVA). The study is ev...
2026-06-17 16:06
2377
RRS® HA Long Lasting awarded Best Injectable in Skin Revitalization at AMWC 2026, reinforcing Skin Tech Pharma Group's leadership in the Skin Builder category
BARCELONA, Spain, June 17, 2026 /PRNewswire/ -- Skin Tech Pharma Group proudly announces that its flagship injectable, RRS® HA LONG LASTING, has been recognized as Best Injectable in the Skin Revitalization category at the AMWC Aesthetic Medicine Awards 2026, one of the most prestigious recogniti...
2026-06-17 08:00
2425
Waterdrop Inc. Reports First Quarter 2026 Unaudited Financial Results, Q1 Net Revenue Up 64.8% Year-over-Year
BEIJING, June 16, 2026 /PRNewswire/ -- On June 16, 2026, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with positive social impact, today announced its unaudited financial results for the first quarter ended March 31, 2026. In the first ...
2026-06-16 21:10
4308
2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
Revolutionizing Treatments for Blood Cancers and Solid Tumors TAIPEI, June 16, 2026 /PRNewswire/ -- On June 16, the Tang Prize in Biopharmaceutical Science announced its 2026 laureates. Three leading scientists in the field of cellular immunotherapy, Drs. Steven A. Rosenberg, Michel Sadelain, an...
2026-06-16 20:30
705
Informa Markets and Thailand's Health Ministry Join Forces To Deliver a Successful Edition of International Healthcare Week 2026 in Bangkok
BANGKOK, June 16, 2026 /PRNewswire/ -- Informa Markets joins forces with Thailand's Department of Health Service Support (DHSS) to unveil International Healthcare Week 2026, a transformative regional healthcare platform that will elevate Thailand's position as a world-leading medical and wellness...
2026-06-16 12:24
2335
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
* Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia * 500,000-1 million people are estimated to be living with FSGS in the territories[1] * Dimerix eligible to ...
2026-06-16 10:53
2908
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 LEHI, Utah, June 15, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapie...
2026-06-15 20:00
2220
Six Regional Organisations Sign MoU to Strengthen Asia's Dengue Response as Cases Rise
Announced at the 9th Asia Dengue Summit in conjunction with ASEAN Dengue Day and the first WHO-recognised World Dengue Day, the MoU establishes a regional framework for knowledge-sharing, advocacy and coordinated dengue action. SINGAPORE, June 15, 2026 /PRNewswire/ -- The Asia Dengue Voice an...
2026-06-15 19:30
3279
Kingworld Medicines Group (01110.HK) Signs MOU to Pursue Exclusive Distribution Rights for Two Lingnan Formula Products
Targeting Full-Channel Sales Coverage in Hong Kong, Mainland China and Cross-border E-commerce HONG KONG, June 15, 2026 /PRNewswire/ -- Kingworld Medicines Group Limited ("Kingworld Medicines" or the "Group", Stock Code: 01110.HK) announced that Morning Gold Medicine Company Limited ("Morning Go...
2026-06-15 13:08
2886
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
* The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. * Post-hoc analysis from the phase 3 SENTRY trial ...
2026-06-14 21:57
2870
Luxel Corporation Appoints KOS, Inc. as Exclusive Distributor in South Korea
FRIDAY HARBOR, Wash., June 13, 2026 /PRNewswire/ -- Luxel Corporation, a global leader in the design and manufacture of ultrathin freestanding polymer and metallized optical bandpass filters, today announced the appointment of KOS, Inc. as its exclusive distribution partner for South Korea, effec...
2026-06-13 06:36
5072
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
BEIJING and BRIDGEWATER, N.J., June 12, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter "Gan & Lee", stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results. SUPER-3: Insul...
2026-06-12 20:00
6807
Week's Top Stories
Most Reposted
Asia Pacific Travellers Seek Familiarity, Practicality, Flexibility Amid Shifting Global Dynamics: Visa Report
[Picked up by 326 media titles]
2026-06-16 10:00
Visa and Mintoak Join Forces to Bring Merchant SaaS Capabilities to Acquirers Across Asia Pacific
[Picked up by 313 media titles]
2026-06-17 11:00NOVVA Group acquires 120 MWp Philippines solar project, anchoring its AI-era power platform in Southeast Asia
[Picked up by 299 media titles]
2026-06-19 11:12
MediThinQ and Synovis Micro Companies Alliance, Inc. Announce Strategic Global Distribution Agreement to Redefine Microsurgery with the SHIYA 3D Visualization Platform
[Picked up by 297 media titles]
2026-06-18 22:01
Affinidi and CardInfoLink Put the Missing Trust Layer for AI Agents into Production
[Picked up by 297 media titles]
2026-06-19 09:00
Most Read
Asia Pacific Travellers Seek Familiarity, Practicality, Flexibility Amid Shifting Global Dynamics: Visa Report
2026-06-16 10:00
6839
All Eyes on Korea: CSOP KOSPI 200 ETF (3121.HK) to List on HKEX Tomorrow
2026-06-17 21:17
5216
